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A Diabetogenic Polypeptide from Bovine 
Adenohypophysis Similar to that Excreted 
in Lipoatrophic Diabetes 
By LAWRENCE H. LOUIS, JEROME W. CONN AND MERLYN C. MINICK 
A polypeptide has been isolated from 
bovine adenohypopbysis which antag- 
onizes the hypoglycemic effect of 
exogenous insulin and which, per se, 
induces loss of carbohydrate tolerance 
in men and dogs. Mild acid hydrolysis 
of the active polypeptide yields a com- 
pound which retains the same biologi- 
cal properties. Characteristics of the 
active principle and its hydrolytic prod- 
uct is the long duration of their activi- 
ties, the greatest intensity of the effects 
TN RECENT COMMUNICATIONS 
being observed between 34 and 60 hours 
after a single intramuscular injection. 
Both substances are devoid of ACTH 
activity. The active polypeptide re- 
sembles closely the insulin antagonist 
isolated from the urine of patients with 
lipoatrophic diabetes previously reported 
from this laboratory. Details of the iso- 
lation and physiologic effects of the ac- 
tive substance and its hydrolytic product 
are described. (Metabolism 15: No. 4, 
April, 308-324, 1966) 
from this laboratory,1*2 the isolation 
1 of an insulin antagonist from the urine of patients with lipoatrophic diabetes 
has been reported. It also was demonstrated that a similar substance was 
present in the urine of a maturity-onset insulin-resistant diabetic without lipo- 
atrophy. The substance was found to be a polypeptide which when adminis- 
tered to either dogs or man exhibited diabetogenic and anti-insulin effects. The 
origin of the active principle had not been determined. 
The present report describes a procedure for the isolation of a similar sub- 
stance from the anterior lobes of bovine pituitary glands. Like the insulin 
antagonist from the urine, the material is also highly active both in dogs and in 
man. 
MATERIALS AND METHODS 
Frozen bovine anterior pituitary glands, obtained from the Armour Pharmaceutical Com- 
pany, Kankakee, Illinois, were treated according to the procedure shown in Figure 1. The 
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PREPARATION OF FRACTION PI 
Fig. 1A 
oxycellulose powder (17-21 per cent COOH, Eastman Chemical Products, Inc., Kingsport, 
Tennessee) employed in step 4 was kept refrigerated and before use was washed successively 
with distilled water, 0.1 N HCL, and distilled water. Electrophoresis of fraction PI on 
cellulose acetate reveals 3 bands, a prominent one with minor bands before and after. 
Elemental analysis of the compound gives the following; C 48.32 per cent, H 7.18 per cent, 
N 15.36 per cent, and S 1.41 per cent. Its isoelectric point is approximately pH 4.1, and the 
average yield is 0.05-0.06 per cent. 
Dogs were maintained on a constant high carbohydrate diet (454 Cm. of Pard and 75 
Gm. of glucose) and the human subjects on a constant 3.200 calorie diet including 300 Gm. 
of carbohydrate before and during all testing procedures. Glucose and insulin tolerance tests 
were carried out before and at various intervals after administration of the material, Twenty- 
four hour urine specimens were collected daily on the human subjects for the estimation of 17- 
ketosteroids,s I7-hydroxysteroids,4 uric acid,5 glucose,a and creatinine.7 The active principle 
from the pituitary tissue was prepared for injection in exactly the same way as that 
previously described* for the insulin antagonist extracted from urine. 
RESULTS 
Fraction PI was tested for biological activity on 3 normal dogs. Figures 2 and 
3 depict examples of the effects obtained on glucose tolerance and on insulin 
tolerance in dogs. 
LIPOATBOPHIC DIABETES 
Conlln”d 
PREPARATION Of FRACTION PI 
311 
Fraction PI also induces glucose intolerance and insulin resistance in man. 
Tables 1, 2 and 3 show the results obtained when 20 mg. was administered 
intramuscularly in a single dose to each of 3 normal volunteers. In each case 
the largest degree of carbohydrate intolerance was observed 8 hours following 
administration of PI. Table 4 shows that urinary excretion of 17-hydroxyster- 
oids, 17-ketosteroids and uric acid did not change significantly. 
Insulin tolerance tests were performed on 2 more healthy subjects. This time 
doses of 20 and 30 mg. of fraction PI were administered intramuscularly on 2 
successive days and the insulin tolerance tests were done 9 and 33 hours after 
the second injection. Figures 4 and 5 indicate the marked insulin resistance 
which was induced. No untoward reacting to this material was observed in any 
subject. 
Further Fractionation of Fraction PI. Biological E#ects of Fraction PIIlC2 
Figure 6 describes the procedure by which fraction PIIICB is obtained from 







DOG F 0 6.6 Kg 
Fig. 2 
fraction PI. Elemental analysis of this compound shows C 51.22 per cent, H 
7.48 per cent, N 14.66 per cent, and S 1.91 per cent. Its isoelectric point is the 
same (approximately pH 4.7) as the urinary fraction IIICB. 
Although fraction PIIIC2 is a hydrolytic product of fraction PI, it possesses 
diabetogenic and anti-insulin properties. However, in one set of experiments 
on the same dog (Fig. 7, 8 and 9), fraction PI was found to be approximately 
twice as potent as fraction PIIICB. 
Biological activity of fraction PIIIC2 was tested on 7 normal young men. 
Three of them received a single dose of 11-12 mg. intramuscularly and all 
developed glucose intolerance. Figures 10 and 11 show the results of subjects 
W. M. B. and J. S. S. Table 5 indicates that urinary excretion of 17-hydroxy- 
steroids, 17-ketosteroids, and uric acid did not change significantly. 
Each of the other 4 subjects was given a larger single dose (40 mg.) of the 
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Fig. 3 
same fraction. Glucose tolerance tests were performed daily for from 7 to 9 
days. Tables 6, 7, 8 and 9 disclose the following: (1) the material induces 
carbohydrate intolerance which persists for 2 to 3 days; (2) renal glycosuria 
becomes evident; and (3) a resurgence of both (1) and (2) at about the sixth 
postinjection day. 
A series of insulin tolerance tests were performed on W. M. B. following a 
12 mg. dose of fraction PIIIC2, the results of which are shown on Figure 12. 
DISCUSSION 
A diabetogenic polypeptide has been isolated from bovine adenohypophsis 
by the same procedure with which a similar diabetogenic polypeptide was 
previously isolated from the urine of patients with lipoatrophic diabetes.2 The 
physical properties of both compounds are very similar and have isoelectric 
points at approximately pH 4.1. Mild acid hydrolysis of both polypeptides 
yields a similar active substance which in both cases has an isoelectric point at 
approximately pH 4.7. 
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Table l.-Efect of Fraction PI upon Glucose Tolerance on 
a h’ormal Subject J. C. M. (22 years, male, 75 Kg.) 
-- 
HOURS AFKR 
INJECTION 20 F 112 1 1 112 2 2 112 3 
mg 
Control 
8 84 174 
33 
56 
81 75 126 133 105 105 105 76 
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104 85 94 
(trace) (trace) (trace) 
113 15 II 




103 107 78 
Table 2.-Effect of Fraction PI upon Glucose Tolerance on 
a Normal Subject J. C, M. (22 years, maZe, 75 Kg.) 
HOURS AFTER 
INJECTION 20 mg ’ l/2 1 1 l/2 2 2 l/2 3 




147 156 156 108 106 89 
(trace) (trace) (trace) (trace) 
147 159 114 115 110 104 
(trace) (trace) 
123 144 104 109 96 86 
(trace) (trace) (trace) (trace) 
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Table 3.-Effect of Fraction PI upon Glucose Tolerance on 
a Normal Subject L. J. B. (22 years, male, 68.3 Kg.) 
Hours after injection 20 mg F l/2 1 11/2 2 2112 3 
Control 81 167 145 130 78 93 90 
8 82 117 158 113 130 103 92 
34 85 154 150 132 123 120 115 
58 83 138 143 149 101 118 83 
104 77 139 135 115 115 89 71 
Table I.-E#ect of Fraction PI upon Urinary 17-OHCS, 
17-K& Creatinine, Uric Acid and Glucose 
SUBJECT DAY INJECTION 17 -0HCS 17-KS CREATININE URIC ACID GLUCOSE 
mg/doy mgtdoy g/day g/day g/day 
I 0 7.2 22.8 2.59 0.940 I .324 
2 0 8.2 22.8 2.37 0.919 I .254 
3 0 7.6 22.8 2.50 0.932 1.324 
4 20 me (IM) 6.0 21.6 2.24 0.735 1.104 
B. A.G. 5 0 6.6 18.6 2.50 0.795 I.216 
6 0 7.4 22.8 2.56 0.786 1.226 
7 0 7.0 19.6 2.49 0.778 I. 188 
ti 0 8.2 19.2 2.47 0.701 I.150 
9 0 6.6 18.0 2.52 0.769 1.234 
IO 0 8.6 21.4 2.56 0.791 1.274 
I 0 10.8 19.0 I.91 0.772 0.838 
2 0 9.4 18.6 1.97 0.805 0.706 
3 J.C.M. 20 mg tlM) 11.6 22.0 2.00 0.805 0.926 
4 0 9.8 19.2 2.01 0.793 0.890 
5 0 IO.2 22.4 2.01 0.739 0.926 
6 0 9.4 19.2 2.12 0.759 0.890 
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Fig. 4 
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Fig. 5 
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PREPARATION OF FRACTION P III C 2 
-CRUDE FRACIION PI IO. 5 gl from step IO 
dissolve in 1M ml 0.1 N HCl,pul nnto Ln~lnng water bath lor I hr. co01 and 
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rash lvilh water and lyophilize 
I ure again as frilc. PI b 
FILTRATE 








dissolve inO. N HCt centrifuge and litter: adjust pH to 3. 5: let sland II 4°C 














I discard I 
I 
PRECIPITATE 
dissolve inO. N HCt liller: adjust lo pH 4.1: lel stand 1 - 2 hrs at 4-C: 
centrifuge: wash ppl with water; lyophilizc 
(frac. PIIICZI 
Fig. 6 
The material is not bovine corticotropin since no evidence of adrenal cortical 
stimulation was observed. Pure bovine growth hormone does not diminish 
carbohydrate tolerance of man .8 It has been shown that bovine growth hor- 
mone can be altered by chemical manipulation after which it may induce 
carbohydrate intolerance in man .9 While this possibility exists, it seems an 
unlikely one since the isolation procedure employed in our work for the isola- 
tion of fraction PI is sufficiently mild that one would not anticipate disruption 
of the growth hormone molecule.* Furthermore, the prolonged reduction in 
*Dr. Don S. Shalch, School of Medicine and Dentistry of the University of Rochester 
showed that our fraction PI has brought about one thousandth the affinity for antigrowth 
hormone antibody as BGH. 
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w. 1. B. 
PORMAL SUBJECT d 72 Kg 21 IRS 
AFTER FRACTION 
GLUCOSE 175 om/Kp BODY WEIGHT (ORALLY) 
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J.S.S. 
NORMAL SUBJECT d 62 Kg 26 IRS 
AFTER FRACTION 
PIUC, (12mg I Ml 
I IS p/Kg BODY WEIGHT ~ORRLLII 
T .- ---T--1 
I l/2 2 2 l/2 3 
HOURS 
Fig. 11 
Table S.-Effect of Fraction PIlICP upon Urinary I7-OHCS, 
1 ?-KS, Creatinine, Uric Acid and Glucose 
-y_ 
SUBJECT MY INJECTION 17-OH cs l7-KS CREATININE URIC ACID 
m#daY mVdaY V&Y g/day _- 
I 0 5.6 6.2 1.66 0.634 
2 0 6.0 I 1.0 1.67 0.795 
3 Ilmq~~ 6.0 6.2 1.63 0.773 
W.M.B. 4 0 5.4 7.3 1.6 I 0.729 
5 : 5.2 5.7 I.73 0.565 
6 62 6.9 










I 0 6.0 12.6 I.59 0.742 0.760 
2 0 7.1 IO.9 1.65 0.636 0.905 
J.S.S. 3 I2 mg(lM1 6.2 13.4 1.67 0.671 0.900 
4 0 6.2 16.2 2.27 I .047 1.260 
5 0 6.3 14.4 2.10 0.903 0.967 
: ii 6.4 19.2 2.40 I.009 I.346 
6.4 IS.6 I .6S Q76 I I.240 
3 0 7.0 18.2 1.94 0.603 0.960 
J.G.E. 4 12rnQ (IMI 6.2 16.4 2.36 I.042 I .360 
5 0 6.2 15.6 2.46 0.944 I.400 
6 0 9.2 17.6 2.23 0.%6 I.400 
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Table 6.-Efiect of Fraction PZZZCB upon Glucose Tolerance on 
a Normul Subject ]. C. M. (22 years, mule, 75 Kg.) 
HOURS AFTER INJECTION 40 F l/2 1 1 l/2 2 2 l/2 3 
mg 













115 106 94 
111 114 106 
55 74 150 
64 80 148 













102 75 141 185 130 108 113 a9 
(+) (+) (trace) 
126 76 120 139 106 91 87 100 
- 
Table 7.-Effect of Fraction PZZZCZ upon Glucose Tolerance on 
a Normal Subject R. F. J. (22 years, mule, 59 Kg.) 
HOURS AFTER INJECTION 40 F 112 1 1 112 2 2 l/2 3 
mg 
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109 95 87 82 88 93 
Table S.-Effect of Fraction PZZZCB UPME Glucose Tolerance on 
a Normal Subject J. S. B. (22 years, male, 79 Kg.) 
HOURS AFTER 
INJECTION 40 F l/2 1 1 mg 
112 2 2 112 3 
Control 84 167 131 112 118 68 84 
12 87 183 162 144 115 84 91 
36 82 172 138 102 107 65 93 
60 76 162 131 72 118 53 57 
84 78 168 119 87 65 61 65 
108 81 168 129 99 74 78 52 




78 190 192 157 134 
(+I (+j (trace 1 
89 219 203 118 116 
I+++) it+) 







Table 9.-EjJect of Fraction PZZZCS upon Glucose Tolerance on 
a Normal Subject L. J. B. (22 years, male, 68 Kg.) 
___ - 
HOURS ARER 
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Fig. 12 
carbohydrate tolerance induced by fraction PIIIC2 should have been accom- 
panied by a rise of plasma free fatty acids and a fall of plasma amino nitrogen 
had the former been the result of a growth hormone effect. 
It thus seems likely that the diabetogenic polypeptide isolated from the 
urine of patients with lipoatrophic diabetes is of adenohypophyseal origin and 
that it is different from the other anterior pituitary polypeptides known to 
diminish carbohydrate tolerance in man. 
REFERENCES 
1. Louis, L. H., and Minick. M. C.: Isola- ist from urine. Metabolism 12:867- 
tion of an insulin antagonist from 886. 1963. 
urine of patients with lipoatrophic di- 3. Chaney, A. L.: 17-ketosteroids in urine. 
abetes. J. Lab. Clin. Med. 60:995-996, Standard methods Clin. Chem. 2:79- 
1962. 85. 1958. 
2. -, Conn. J, W.. and Minick. M. C.: 4. Silber. R. H., and Porter, C. C.: The 
Lipoatrophic diabetes: isolation and determination of 17, 21-dihydroxy-20- 
characterization of an insulin antagon- ketosteroids in urine and plasma. J. 
324 LOUIS, CONN AND MINICK 
Biol. Chem. 210:923-932, 1954. 
5. Forsham, P. H., Thorn, G. W., Prunty, F. 
T. Q., and Hills, A. G.: Clinical stud- 
ies with pituitary adrenocorticotropin. 
J. Clin. Endocrinol. 8:15X%, 1948. 
6. Somogyi, M.: Notes on sugar determina- 
tion. J. Biol. Chem. 19519, 1952. 
7. Kingsley, G. R., and Schaffert. R. R.: 
Creatinine. Standard Methods Clin. 
Chem. 1:55-59, 1953. 
8. Lewis. R. A., Klein, R.. and Wilkins, L.: 
The effect of pituitary growth hor- 
mone in dwarfism with osseous retar- 
dation and hypoglucemia and in a cre- 
tin treated with thyroid. J. Clin. In- 
vest. 293460-464. 1950. 
9. Sonenberg. M., Free. C. A., Dellacha, J. 
M.. Bonadonna, G.. Haymowitz. A.. 
and Nadler. A. C.: The metabolic 
effects in man of bovine growth hor- 
mone digested with trypsin. J. Clin. 
Invest. 44: 1099, 1965. 
